2025-03-17
On February 27, 2025, Triastek announced that a proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This regulatory milestone follows the prior IND clearance of this product by China's National Medical Products Administration (NMPA) in January 2024.
Atrial fibrillation (AF), the most common type of treated heart arrhythmia prevalent in clinical practice, affects approximately 1%–2% of the general population, with global prevalence estimates ranging between 30 to 100 million cases [1]. Anticoagulation therapy remains the cornerstone therapeutic intervention for stroke prevention in patients with AF. Among available therapeutic options, NOACs have emerged as the preferred pharmacologic agents due to their superior safety and efficacy profiles compared to traditional therapies. Reflecting this clinical advantage, NOACs are recommended as first-line treatment in leading guidelines, including those from the American Heart Association (AHA), European Society of Cardiology (ESC), and Asia-Pacific Heart Rhythm Society (APHRS) [2–4].
T20G is being developed by using a novel dosage form (or drug delivery system) under the FDA's 505(b)(2) New Drug Application (NDA) pathway. Triastek holds exclusive global intellectual and commercialization rights for this innovative therapeutic candidate.
Leveraging Triastek's proprietary Melt Extrusion Deposition with Micro-Injection Molding (MED&MIM) process, T20G features the company's patented 3D Microstructure for Gastric Retention (3DμS®-GR) platform to enable once-daily oral administration. This optimized dosing regimen offers advantages over the twice-daily dosing required by the reference listed drug (RLD), potentially improving patient adherence and simplifying dosing management. During its gastric retention phase, T20G enables sustained release of the active pharmaceutical ingredient (API), facilitating drug absorption in the upper gastrointestinal tract, which significantly enhances its oral absorption.
Dr. Feihuang Deng, VP Technology of Triastek, said: "With T20G receiving IND clearance in both China and the U.S., Triastek has achieved a new milestone in the field of gastric retention drug delivery. Building on this dual regulatory recognition, we will accelerate the development of T20G to provide high-quality pharmaceutical products to patients worldwide."
Reference:
[1] MAIMAITI Aerzuguli, TUERXUN Maiwujiudai, NIJIATI Abidan,et al.Research progress in risk factors of thromboembolism among patients with atrial fibrillation[J]. J Pract Electocardiol,2024,33(1):93-97,103.
[2] Van Gelder IC, Rienstra M, Bunting KV, et al., ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2024;ehae176.
[3] Joglar JA, Chung MK, Armbruster AL, et al., Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation2024;149:e1-156.
[4] Chao TF, Joung B, Takahashi Y, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2022;122(1):20-47.
BD@triastek.com
苏ICP备17053162号 苏公网安备 32011502011777号
All Rights Reserved
Copyright © 2025 (TRIASTEK)
Contact Us
BD@triastek.comCOPYRIGHT © 2025 TRIASTEK. 苏ICP备17053162号
DIGITAL By VTHINK